JP2015528508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528508A5 JP2015528508A5 JP2015532064A JP2015532064A JP2015528508A5 JP 2015528508 A5 JP2015528508 A5 JP 2015528508A5 JP 2015532064 A JP2015532064 A JP 2015532064A JP 2015532064 A JP2015532064 A JP 2015532064A JP 2015528508 A5 JP2015528508 A5 JP 2015528508A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- dimethyl
- alkoxy
- amine
- quinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- -1 cyano, hydroxyl Chemical group 0.000 claims 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- QODPGRHWJBWTJC-UHFFFAOYSA-N 6-tert-butylsulfonyl-n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-(2-methoxyethoxy)quinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C(C)(C)C)C(OCCOC)=CC2=NC=CC=1NC1=NNC(C)=C1C QODPGRHWJBWTJC-UHFFFAOYSA-N 0.000 claims 3
- 208000009766 Blau syndrome Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- BFDDPFRPBQXQBX-GFCCVEGCSA-N (2r)-1-[6-tert-butylsulfonyl-4-[(4,5-dimethyl-1h-pyrazol-3-yl)amino]quinolin-7-yl]oxypropan-2-ol Chemical compound C=12C=C(S(=O)(=O)C(C)(C)C)C(OC[C@H](O)C)=CC2=NC=CC=1NC1=NNC(C)=C1C BFDDPFRPBQXQBX-GFCCVEGCSA-N 0.000 claims 1
- BFDDPFRPBQXQBX-LBPRGKRZSA-N (2s)-1-[6-tert-butylsulfonyl-4-[(4,5-dimethyl-1h-pyrazol-3-yl)amino]quinolin-7-yl]oxypropan-2-ol Chemical compound C=12C=C(S(=O)(=O)C(C)(C)C)C(OC[C@@H](O)C)=CC2=NC=CC=1NC1=NNC(C)=C1C BFDDPFRPBQXQBX-LBPRGKRZSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- HOTBTVYQQMHEBB-UHFFFAOYSA-N 1-[6-tert-butylsulfonyl-4-[(4,5-dimethyl-1h-pyrazol-3-yl)amino]quinolin-7-yl]oxy-2-methylpropan-2-ol Chemical compound CC1=C(C)NN=C1NC1=CC=NC2=CC(OCC(C)(C)O)=C(S(=O)(=O)C(C)(C)C)C=C12 HOTBTVYQQMHEBB-UHFFFAOYSA-N 0.000 claims 1
- HZDJLSITORIPGT-UHFFFAOYSA-N 2-[4-[(4,5-dimethyl-1h-pyrazol-3-yl)amino]-7-methoxyquinolin-6-yl]sulfonyl-2-methylpropan-1-ol Chemical compound C=12C=C(S(=O)(=O)C(C)(C)CO)C(OC)=CC2=NC=CC=1NC1=NNC(C)=C1C HZDJLSITORIPGT-UHFFFAOYSA-N 0.000 claims 1
- LSTLSXLHIRBYFQ-UHFFFAOYSA-N 2-[4-[(4,5-dimethyl-1h-pyrazol-3-yl)amino]-7-methoxyquinolin-6-yl]sulfonylethanol Chemical compound C=12C=C(S(=O)(=O)CCO)C(OC)=CC2=NC=CC=1NC1=NNC(C)=C1C LSTLSXLHIRBYFQ-UHFFFAOYSA-N 0.000 claims 1
- HRBKEPLXBIHJME-UHFFFAOYSA-N 2-[6-tert-butylsulfonyl-4-[(4,5-dimethyl-1h-pyrazol-3-yl)amino]quinolin-7-yl]oxyethanol Chemical compound CC1=C(C)NN=C1NC1=CC=NC2=CC(OCCO)=C(S(=O)(=O)C(C)(C)C)C=C12 HRBKEPLXBIHJME-UHFFFAOYSA-N 0.000 claims 1
- OVPZGUMHWDAVSH-UHFFFAOYSA-N 6-(2,2-dimethyloxan-4-yl)sulfonyl-n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-methoxyquinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C3CC(C)(C)OCC3)C(OC)=CC2=NC=CC=1NC1=NNC(C)=C1C OVPZGUMHWDAVSH-UHFFFAOYSA-N 0.000 claims 1
- SHJUBFAKVSHFJQ-OCZCAGDBSA-N 6-[(2r,6s)-2,6-dimethyloxan-4-yl]sulfonyl-n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-methoxyquinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C3C[C@@H](C)O[C@@H](C)C3)C(OC)=CC2=NC=CC=1NC1=NNC(C)=C1C SHJUBFAKVSHFJQ-OCZCAGDBSA-N 0.000 claims 1
- QWECBUNTPLWDBL-UHFFFAOYSA-N 6-tert-butylsulfonyl-4-[(4,5-dimethyl-1H-pyrazol-3-yl)amino]quinolin-7-ol Chemical compound CC1=C(C)NN=C1NC1=CC=NC2=CC(O)=C(S(=O)(=O)C(C)(C)C)C=C12 QWECBUNTPLWDBL-UHFFFAOYSA-N 0.000 claims 1
- PLYPDBCKMUBDTF-UHFFFAOYSA-N 6-tert-butylsulfonyl-7-(2,2-difluoroethoxy)-n-(4,5-dimethyl-1h-pyrazol-3-yl)quinolin-4-amine Chemical compound CC1=C(C)NN=C1NC1=CC=NC2=CC(OCC(F)F)=C(S(=O)(=O)C(C)(C)C)C=C12 PLYPDBCKMUBDTF-UHFFFAOYSA-N 0.000 claims 1
- DPILGXGHKJEOAS-UHFFFAOYSA-N 6-tert-butylsulfonyl-7-(difluoromethoxy)-n-(4,5-dimethyl-1h-pyrazol-3-yl)quinolin-4-amine Chemical compound CC1=C(C)NN=C1NC1=CC=NC2=CC(OC(F)F)=C(S(=O)(=O)C(C)(C)C)C=C12 DPILGXGHKJEOAS-UHFFFAOYSA-N 0.000 claims 1
- DPSNWHXNCQBYAH-UHFFFAOYSA-N 6-tert-butylsulfonyl-7-methoxy-n-[4-methyl-5-(trifluoromethyl)-1h-pyrazol-3-yl]quinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C(C)(C)C)C(OC)=CC2=NC=CC=1NC1=NNC(C(F)(F)F)=C1C DPSNWHXNCQBYAH-UHFFFAOYSA-N 0.000 claims 1
- LSBUSOIHRLJSJM-UHFFFAOYSA-N 6-tert-butylsulfonyl-n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-(2,2,2-trifluoroethoxy)quinolin-4-amine Chemical compound CC1=C(C)NN=C1NC1=CC=NC2=CC(OCC(F)(F)F)=C(S(=O)(=O)C(C)(C)C)C=C12 LSBUSOIHRLJSJM-UHFFFAOYSA-N 0.000 claims 1
- VENUDGUYMCDYAB-UHFFFAOYSA-N 6-tert-butylsulfonyl-n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-(3-methoxypropoxy)quinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C(C)(C)C)C(OCCCOC)=CC2=NC=CC=1NC1=NNC(C)=C1C VENUDGUYMCDYAB-UHFFFAOYSA-N 0.000 claims 1
- UVCJVWDOTPZNJM-UHFFFAOYSA-N 6-tert-butylsulfonyl-n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-ethoxyquinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C(C)(C)C)C(OCC)=CC2=NC=CC=1NC1=NNC(C)=C1C UVCJVWDOTPZNJM-UHFFFAOYSA-N 0.000 claims 1
- SNLKRSSBDMHRFL-UHFFFAOYSA-N 6-tert-butylsulfonyl-n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-fluoroquinolin-4-amine Chemical compound CC1=C(C)NN=C1NC1=CC=NC2=CC(F)=C(S(=O)(=O)C(C)(C)C)C=C12 SNLKRSSBDMHRFL-UHFFFAOYSA-N 0.000 claims 1
- LHPFRDAGGDMRMZ-UHFFFAOYSA-N 6-tert-butylsulfonyl-n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-methoxyquinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C(C)(C)C)C(OC)=CC2=NC=CC=1NC1=NNC(C)=C1C LHPFRDAGGDMRMZ-UHFFFAOYSA-N 0.000 claims 1
- SVARURAGDUBTCW-UHFFFAOYSA-N 7-(difluoromethoxy)-n-(4,5-dimethyl-1h-pyrazol-3-yl)-6-(oxan-4-ylsulfonyl)quinolin-4-amine Chemical compound CC1=C(C)NN=C1NC1=CC=NC2=CC(OC(F)F)=C(S(=O)(=O)C3CCOCC3)C=C12 SVARURAGDUBTCW-UHFFFAOYSA-N 0.000 claims 1
- GMWIWJMSCHALJV-UHFFFAOYSA-N 7-methoxy-n-[4-methyl-5-(trifluoromethyl)-1h-pyrazol-3-yl]-6-(oxan-4-ylsulfonyl)quinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C3CCOCC3)C(OC)=CC2=NC=CC=1NC1=NNC(C(F)(F)F)=C1C GMWIWJMSCHALJV-UHFFFAOYSA-N 0.000 claims 1
- LHUXIXHXMCIUBN-UHFFFAOYSA-N 7-methoxy-n-[4-methyl-5-(trifluoromethyl)-1h-pyrazol-3-yl]-6-propan-2-ylsulfonylquinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C(C)C)C(OC)=CC2=NC=CC=1NC1=NNC(C(F)(F)F)=C1C LHUXIXHXMCIUBN-UHFFFAOYSA-N 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 108090000426 Caspase-1 Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- UTGFZERHPKWOOY-UHFFFAOYSA-N n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-methoxy-6-(2-methoxyethylsulfonyl)quinolin-4-amine Chemical compound C1=CN=C2C=C(OC)C(S(=O)(=O)CCOC)=CC2=C1NC1=NNC(C)=C1C UTGFZERHPKWOOY-UHFFFAOYSA-N 0.000 claims 1
- GTRTXSSFSXXYFL-UHFFFAOYSA-N n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-methoxy-6-(4-methyloxan-4-yl)sulfonylquinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C3(C)CCOCC3)C(OC)=CC2=NC=CC=1NC1=NNC(C)=C1C GTRTXSSFSXXYFL-UHFFFAOYSA-N 0.000 claims 1
- CXRQMMOWWNSBTM-UHFFFAOYSA-N n-(4,5-dimethyl-1h-pyrazol-3-yl)-7-methoxy-6-(oxan-4-ylsulfonyl)quinolin-4-amine Chemical compound C=12C=C(S(=O)(=O)C3CCOCC3)C(OC)=CC2=NC=CC=1NC1=NNC(C)=C1C CXRQMMOWWNSBTM-UHFFFAOYSA-N 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700536P | 2012-09-13 | 2012-09-13 | |
| US61/700,536 | 2012-09-13 | ||
| US201361767378P | 2013-02-21 | 2013-02-21 | |
| US61/767,378 | 2013-02-21 | ||
| PCT/US2013/059600 WO2014043437A1 (en) | 2012-09-13 | 2013-09-13 | Amino-quinolines as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528508A JP2015528508A (ja) | 2015-09-28 |
| JP2015528508A5 true JP2015528508A5 (cg-RX-API-DMAC7.html) | 2016-07-14 |
| JP6258331B2 JP6258331B2 (ja) | 2018-01-10 |
Family
ID=50278701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532064A Expired - Fee Related JP6258331B2 (ja) | 2012-09-13 | 2013-09-13 | キナーゼ阻害剤としてのアミノ−キノリン |
Country Status (21)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY33549A (es) * | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
| WO2012122011A2 (en) | 2011-03-04 | 2012-09-13 | Glaxosmithkline Llc | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| BR112015019624A2 (pt) | 2013-02-21 | 2017-07-18 | Glaxosmithkline Ip Dev Ltd | quinazolinas como inibidores de quinase |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017062500A2 (en) | 2015-10-05 | 2017-04-13 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| CN107158385B (zh) * | 2016-03-14 | 2020-07-14 | 苏州大学 | Rip3抑制剂在制备抗血小板血栓药物中的用途 |
| JP2019514878A (ja) | 2016-04-20 | 2019-06-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｒｉｐｋ２阻害剤を含むコンジュゲート |
| WO2020094613A1 (en) | 2018-11-06 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nod2 inhibitors for the treatment of hereditary periodic fevers |
| CN114014890A (zh) * | 2021-03-12 | 2022-02-08 | 爱科诺生物医药(香港)有限公司 | 具有rip2激酶抑制活性的化合物，包含其的药物组合物，及其应用 |
| WO2025078493A1 (en) | 2023-10-11 | 2025-04-17 | Institut National de la Santé et de la Recherche Médicale | Local administration of ripk2 inhibitors for the curative treatment of allergic asthma |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916135A (en) | 1989-05-08 | 1990-04-10 | Hoechst Roussel Pharmaceuticals Inc. | N-heteroaryl-4-quinolinamines |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| US6046206A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
| WO1998005647A1 (en) | 1996-08-01 | 1998-02-12 | Dow Agrosciences Llc | Quinolinium derivatives having fungicidal activity |
| WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| NZ510210A (en) | 1998-10-01 | 2003-06-30 | Astrazeneca Ab | 4-phenylamino substituted quinazoline or quinoline derivatives useful for treating cytokine mediated diseases or conditions |
| GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| CN1391562A (zh) | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 用作药物的喹唑啉衍生物 |
| EP1294709A2 (en) | 2000-01-28 | 2003-03-26 | AstraZeneca AB | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| MXPA02007957A (es) | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| CA2415469A1 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
| GB0104422D0 (en) | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| WO2003026665A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| MXPA04006260A (es) | 2001-12-24 | 2005-03-31 | Astrazeneca Ab | Derivados de quinazolina sustituidos como inhibidores de cinasas aurora. |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| US20040122161A1 (en) | 2002-12-21 | 2004-06-24 | Paul Charles W. | Hot melt adhesive based on acrylic block copolymers |
| AU2003290313B2 (en) | 2002-12-24 | 2007-05-10 | Astrazeneca Ab | Phosphonooxy quinazoline derivatives and their pharmaceutical use |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| JP2007501854A (ja) | 2003-05-27 | 2007-02-01 | ファイザー・プロダクツ・インク | 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類 |
| JP5129957B2 (ja) | 2003-07-03 | 2013-01-30 | ミリアド ジェネティクス， インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン |
| BRPI0414489A8 (pt) | 2003-09-16 | 2019-01-15 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| AU2005249503B2 (en) | 2003-11-10 | 2011-08-25 | Vertex Pharmaceuticals Incorporated | ICE inhibitors for the treatment of autoinflammatory diseases |
| WO2005063739A1 (en) | 2003-12-23 | 2005-07-14 | Pfizer Inc. | Novel quinoline derivatives |
| AU2005223610B2 (en) | 2004-03-23 | 2008-05-29 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| WO2005115145A2 (en) | 2004-05-20 | 2005-12-08 | Wyeth | Quinone substituted quinazoline and quinoline kinase inhibitors |
| WO2005120509A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| FR2873695A1 (fr) | 2004-07-30 | 2006-02-03 | Palumed Sa | Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien |
| BRPI0519267A2 (pt) | 2004-12-22 | 2009-01-06 | Bayer Schering Pharma Ag | derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CA2603748A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| ITMI20052008A1 (it) | 2005-10-21 | 2007-04-22 | Ctg Pharma S R L | Nuovi antimalarici derivati della 4-aminochinolina |
| FR2902100A1 (fr) | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
| US7511063B2 (en) | 2006-08-16 | 2009-03-31 | Schering Corporation | High affinity quinoline-based kinase ligands |
| JP2008063278A (ja) | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | １−ピリジン−４−イル−インドール類の製造方法 |
| US20080221132A1 (en) | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
| TW200829555A (en) | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| WO2008119771A2 (en) | 2007-03-30 | 2008-10-09 | Clanotech Ab | Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors |
| BRPI0810462A2 (pt) | 2007-04-23 | 2014-10-14 | Sanofi Aventis | Derivados de quinolina-carboxamida como antagonistas de p2y12 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| TW200908982A (en) | 2007-06-01 | 2009-03-01 | Wyeth Corp | Treatment of imatinib resistant leukemia |
| CN101362719B (zh) | 2007-08-06 | 2012-04-18 | 北京师范大学 | 喹啉类衍生物以及包含其的组合物 |
| US7790746B2 (en) | 2007-10-12 | 2010-09-07 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
| US7939546B2 (en) | 2007-10-12 | 2011-05-10 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
| GB0801416D0 (en) | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| DE102008062566A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
| WO2011112588A2 (en) | 2010-03-08 | 2011-09-15 | Case Western Reserve University | Compositions and methods for treating inflammatory disorders |
| US20130023532A1 (en) | 2010-03-26 | 2013-01-24 | Casillas Linda N | Indazolyl-pyrimidines as kinase inhibitors |
| JP2013523658A (ja) | 2010-03-26 | 2013-06-17 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのピラゾリル‐ピリミジン |
| WO2011123609A1 (en) | 2010-03-31 | 2011-10-06 | Glaxo Group Limited | Imidazolyl-imidazoles as kinase inhibitors |
| JP2013526484A (ja) | 2010-05-07 | 2013-06-24 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのアミノ‐キノリン |
| UY33549A (es) | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CA2820709C (en) * | 2011-02-28 | 2016-02-16 | Sunshine Lake Pharma Co., Ltd. | Substituted quinoline compounds and methods of use |
| WO2012122011A2 (en) | 2011-03-04 | 2012-09-13 | Glaxosmithkline Llc | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| BR112015019624A2 (pt) | 2013-02-21 | 2017-07-18 | Glaxosmithkline Ip Dev Ltd | quinazolinas como inibidores de quinase |
-
2013
- 2013-09-11 TW TW102132714A patent/TW201425307A/zh unknown
- 2013-09-11 AR ARP130103248A patent/AR092530A1/es unknown
- 2013-09-13 ES ES13836616T patent/ES2713172T3/es active Active
- 2013-09-13 EP EP13836616.6A patent/EP2895167B1/en active Active
- 2013-09-13 PE PE2015000276A patent/PE20150774A1/es not_active Application Discontinuation
- 2013-09-13 SG SG11201500973WA patent/SG11201500973WA/en unknown
- 2013-09-13 CN CN201380045559.XA patent/CN104602692B/zh not_active Expired - Fee Related
- 2013-09-13 AU AU2013315387A patent/AU2013315387B2/en not_active Ceased
- 2013-09-13 BR BR112015004967A patent/BR112015004967A2/pt active Search and Examination
- 2013-09-13 CA CA2883155A patent/CA2883155A1/en not_active Abandoned
- 2013-09-13 WO PCT/US2013/059600 patent/WO2014043437A1/en not_active Ceased
- 2013-09-13 JP JP2015532064A patent/JP6258331B2/ja not_active Expired - Fee Related
- 2013-09-13 MX MX2015003275A patent/MX2015003275A/es unknown
- 2013-09-13 EA EA201590552A patent/EA027984B1/ru not_active IP Right Cessation
- 2013-09-13 KR KR1020157006177A patent/KR20150053920A/ko not_active Withdrawn
- 2013-09-13 US US14/396,559 patent/US9216965B2/en not_active Expired - Fee Related
-
2015
- 2015-02-09 IL IL237158A patent/IL237158A0/en unknown
- 2015-02-17 PH PH12015500345A patent/PH12015500345A1/en unknown
- 2015-03-12 CL CL2015000615A patent/CL2015000615A1/es unknown
- 2015-03-13 CR CR20150133A patent/CR20150133A/es unknown
- 2015-03-13 DO DO2015000059A patent/DOP2015000059A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528508A5 (cg-RX-API-DMAC7.html) | ||
| JP2014525937A5 (cg-RX-API-DMAC7.html) | ||
| JP2014513110A5 (cg-RX-API-DMAC7.html) | ||
| JP2016507581A5 (cg-RX-API-DMAC7.html) | ||
| JP2018515555A5 (cg-RX-API-DMAC7.html) | ||
| JP6661749B2 (ja) | Ｒｏｒガンマモジュレータとしての新規化合物 | |
| JP2012500277A5 (cg-RX-API-DMAC7.html) | ||
| AU2011297889B2 (en) | Pharmaceutically active compounds as Axl inhibitors | |
| RU2013143292A (ru) | Триазолопиридиновые соединения как ингибиторы киназы pim | |
| HRP20171999T1 (hr) | Novi derivati aminopirimidina | |
| AR092530A1 (es) | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento | |
| RU2019123529A (ru) | Соединение хиназолина | |
| JP2013510124A5 (cg-RX-API-DMAC7.html) | ||
| JP2017523152A5 (cg-RX-API-DMAC7.html) | ||
| HRP20151001T1 (hr) | Sredstva kao induktori apoptoze za lijeäśenje raka te imunih i autoimunih bolesti | |
| JP2013510125A5 (cg-RX-API-DMAC7.html) | ||
| EA201071232A1 (ru) | Триазины как ингибиторы киназы pi3 и mtor | |
| SI2895174T1 (en) | The prodrugs of the amino quinazoline kinase inhibitor | |
| CA2551508A1 (en) | Novel quinoline derivatives | |
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| JP2015529681A5 (cg-RX-API-DMAC7.html) | ||
| ME02867B (me) | Nova jedinjenja | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| JP2019531279A5 (cg-RX-API-DMAC7.html) | ||
| JP2019505594A5 (cg-RX-API-DMAC7.html) |